Biosimilars Cusp Market - Biosimilars on the Cusp of a New Era

1
Biosimilars - Biosimilars on the cusp of a new
era Market Research Report www.bigmarketresearch.
com
2
Report Description
About Biosimilars Market The biosimilars market
is undergoing rapid change with developments such
as the recent approvals of infliximab and
trastuzumab heralding a new era. In order to keep
up with the pace of change in the marketplace,
regulatory agencies have been developing updated
guidance around the development and approval of
biosimilars, but there is still a lack of
consistency, particularly between the two leading
agencies - the FDA and EMA. Moreover, there are
some concerns around biosimilar use, for example
with physicians worried about how similar certain
drugs are and whether they can safely be used in
particular patient populations such as
transplant, due to the potential for variance in
efficacy and tolerability. Despite this, it is
expected that the biosimilar market will continue
to experience significant growth in the next five
to ten years, being driven by the extensive
pipeline and the number of companies becoming
involved in this area - including some big pharma
who are seizing the opportunity to develop
biosimilar versions of competitor products in
order to ensure they are able to compete at all
levels. Get More Details At http//www.bigmarket
research.com/biosimilars-biosimilars-on-the-cusp-o
f-a-new-era-market
3
Report Description
Scope The report covers the following key areas
- - An overview and background about biosimilars
- what they are and a timeline of their
development - Key concerns regarding the
development and use of biosimilars - An overview
of the issues around automatic substitution with
biosimilars - The regulatory landscape for
biosimilars, including a comparison of FDA and
EMA guidelines - Recent developments in the
biosimilars market including the anticipated
patent expiries of key biologic products and
launches of new biosimilar products - The
position of HTA and PR agencies on biosimilars -
Industry perspective on the expected impact of
biosimilars - The biosimilars pipeline and key
future developments - Key companies involved in
biosimilars - The way forward for
industry Enquiry about Report _at_
http//www.bigmarketresearch.com/report-enquiry/13
2509
4
Report Description

• Key Reasons to Purchase
• The report will Provide an in-depth insight into
  recent biosimilar regulatory developments
  including a comparison of the processes used in
  different markets and the guidance being
  implemented.
• Assess the biosimilars pipeline including where
  development is currently focused and the
  potential impact new biosimilars will have on the
  marketplace.
• Highlight industry opinions towards biosimilars
  and their expected impact in different therapy
  areas and how industry can meet the challenges
  being presented by biosimilar development and
  launches.
• - Provide an understanding about the key
  concerns around biosimilar development and use,
  including manufacturing concerns and issues
  around automatic substitution.
• - Provide an overview of the key companies
  involved in the biosimilar market including
  an analysis of where the majority of biosimilar
  companies are located, the markets in which
  they operate and the future outlook.

5
Table Of Content
Executive summary Methodology Biosimilars an
overview Key concerns surrounding biosimilar
use Automatic substitution A changing regulatory
landscape EMA guidelines FDA guidelines Considerat
ions for the rest of the world Recent
developments in the biosimilars market New
biosimilar launches Government/agency
opinions Implications for the marketplace Get
complete TOC here _at_ http//www.bigmarketresearch.c
om/biosimilars-biosimilars-on-the-cusp-of-a-new-er
a-market
6
FOR MORE DETAILS
Visit us at
http//www.bigmarketresearch.com/biosimilars-biosi
milars-on-the-cusp-of-a-new-era-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone]E-MAIL
sales_at_bigmarketresearch.com